Preventive treatment to protect against AIDS for two months is now available in France. The High Authority of Health has approved the reimbursement of the injectable Prep, an antiretroviral that avoids the daily intake of a tablet. This new form of Prep, called Apretude, is based on cabotegravir and will be administered through an injection every two months.

This new treatment is a significant development in the fight against HIV, as it has shown superior efficacy compared to the tablet form of Prep in studies conducted on men who have sex with men, as well as women and adolescents in Africa. The price of the treatment is still being negotiated between the laboratory ViiV Healthcare and the French authorities.

Dr. Hugues Cordel, an infectious disease specialist at the hospital, stated that the arrival of this new treatment is great news and will strengthen the tools available to combat the HIV epidemic. The injectable form has proven to be more effective in preventing HIV infection, and its approval for reimbursement will make it accessible to certain populations at risk.

The introduction of this new treatment marks a significant milestone in the ongoing efforts to control the spread of HIV. With the availability of an injectable form of Prep that only needs to be administered every two months, individuals at risk of HIV infection will have an additional option for protection. This development highlights the importance of ongoing research and innovation in the field of HIV prevention and treatment.

The fight against HIV/AIDS continues to evolve, with new treatments and preventive measures being developed to address the changing needs of at-risk populations. The approval of the injectable Prep in France is a step forward in providing more options for individuals to protect themselves from HIV infection. It is crucial to continue raising awareness about the importance of preventive measures and regular testing for HIV to effectively control the spread of the virus.

Overall, the approval of the injectable Prep in France represents a significant advancement in HIV prevention and treatment. It offers a more convenient and effective option for individuals at risk of HIV infection, and its availability for reimbursement will make it more accessible to those who need it. This development underscores the importance of ongoing research and innovation in the field of HIV/AIDS to combat the epidemic effectively.